Addendum: Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy

PDF  |  How to cite

Oncotarget. 2023; 14:502-502. https://doi.org/10.18632/oncotarget.28445

Metrics: PDF 405 views  |   ?  

Stephanie A. Toll1,2,*, Hung N. Tran3,*, Jennifer Cotter2,4, Alexander R. Judkins2,4, Benita Tamrazi2,5, Jaclyn A. Biegel2,4, Girish Dhall1,2, Nathan J. Robison1,2, Kaaren Waters1, Palak Patel2, Robert Cooper3,* and Ashley S. Margol1,2,*

1Division of Hematology, Oncology and Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles, Los Angeles, CA, USA
2University of Southern California Keck School of Medicine, Los Angeles, CA, USA
3Kaiser Permanente Southern California, Los Angeles, CA, USA
4Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA
5Department of Radiology and Imaging, Children’s Hospital Los Angeles, Los Angeles, CA, USA
*These authors have contributed equally to this work

Published: May 19, 2023

Copyright: © 2023 Toll et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Signed HIPPA forms from the parents of the 2 patients who were alive at the time of manuscript submission were obtained.

Original article: Oncotarget. 2019; 10:551-557. DOI: https://doi.org/10.18632/oncotarget.26560.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28445